Steven Cohen's TVTX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 478,860 shares of Travere Therapeutics, Inc. (TVTX) worth $27.2 M, representing 0.03% of the portfolio. First purchased in 2020-Q4, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in TVTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2023, adding 1.79 M shares. Largest reduction occurred in Q3 2023, reducing 1.77 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Travere Therapeutics (TVTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Travere Therapeutics (TVTX) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +478,860 | New Buy | 478,860 | $56.81 |
| Q1 2026 | -173,383 | Sold Out | 0 | $0.00 |
| Q4 2025 | +173,383 | New Buy | 173,383 | $38.21 |
| Q3 2025 | -167,896 | Sold Out | 0 | $0.00 |
| Q2 2025 | +167,896 | New Buy | 167,896 | $14.80 |
| Q3 2024 | -320,580 | Sold Out | 0 | $0.00 |
| Q2 2024 | -551,520 | Reduce 63.24% | 320,580 | $8.22 |
| Q1 2024 | +872,100 | New Buy | 872,100 | $7.71 |
| Q4 2023 | -13,572 | Sold Out | 0 | $0.00 |
| Q3 2023 | -1.77 M | Reduce 99.24% | 13,572 | $8.94 |
| Q2 2023 | +1.79 M | New Buy | 1.79 M | $15.36 |
| Q4 2022 | -327,706 | Sold Out | 0 | $0.00 |
| Q3 2022 | +327,706 | New Buy | 327,706 | $24.64 |
| Q2 2022 | -33,300 | Sold Out | 0 | $0.00 |
| Q1 2022 | +33,300 | New Buy | 33,300 | $25.77 |
| Q2 2021 | -1.61 M | Sold Out | 0 | $0.00 |
| Q1 2021 | +987,126 | Add 158.96% | 1.61 M | $24.97 |
| Q4 2020 | +621,000 | New Buy | 621,000 | $27.25 |
Steven Cohen's Travere Therapeutics Investment FAQs
Steven Cohen first purchased Travere Therapeutics, Inc. (TVTX) in Q4 2020, acquiring 621,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Travere Therapeutics, Inc. (TVTX) for 18 quarters since Q4 2020.
Steven Cohen's largest addition to Travere Therapeutics, Inc. (TVTX) was in Q2 2023, adding 1,785,979 shares worth $27.43 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 478,860 shares of Travere Therapeutics, Inc. (TVTX), valued at approximately $27.2 M.
As of the Q2 2026 filing, Travere Therapeutics, Inc. (TVTX) represents approximately 0.03% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Travere Therapeutics, Inc. (TVTX) was 1,785,979 shares, as reported at the end of Q2 2023.